SA516371701B1 - مركب ترايازين واستخدامه للأغراض الطبية - Google Patents

مركب ترايازين واستخدامه للأغراض الطبية Download PDF

Info

Publication number
SA516371701B1
SA516371701B1 SA516371701A SA516371701A SA516371701B1 SA 516371701 B1 SA516371701 B1 SA 516371701B1 SA 516371701 A SA516371701 A SA 516371701A SA 516371701 A SA516371701 A SA 516371701A SA 516371701 B1 SA516371701 B1 SA 516371701B1
Authority
SA
Saudi Arabia
Prior art keywords
alkyl
compound
tyas
mmol
mixture
Prior art date
Application number
SA516371701A
Other languages
Arabic (ar)
English (en)
Inventor
ميتاني ايكو
هوتا تاكاهيرو
اويدا ماساتوشي
ياماشيتا ماساكي
ناجاموري هيرونوبو
ناكاجاو يوشي
Original Assignee
.جابان توباكو انك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by .جابان توباكو انك filed Critical .جابان توباكو انك
Publication of SA516371701B1 publication Critical patent/SA516371701B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SA516371701A 2014-02-20 2016-08-18 مركب ترايازين واستخدامه للأغراض الطبية SA516371701B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20
PCT/JP2015/054519 WO2015125842A1 (ja) 2014-02-20 2015-02-19 トリアジン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
SA516371701B1 true SA516371701B1 (ar) 2019-01-21

Family

ID=53878341

Family Applications (1)

Application Number Title Priority Date Filing Date
SA516371701A SA516371701B1 (ar) 2014-02-20 2016-08-18 مركب ترايازين واستخدامه للأغراض الطبية

Country Status (32)

Country Link
US (3) US20150266834A1 (enExample)
EP (2) EP3456713A1 (enExample)
JP (4) JP6461637B2 (enExample)
KR (1) KR102360699B1 (enExample)
CN (1) CN106232585B (enExample)
AR (1) AR099498A1 (enExample)
AU (1) AU2015219920B2 (enExample)
BR (1) BR112016018341B1 (enExample)
CA (1) CA2936408C (enExample)
CL (1) CL2016002091A1 (enExample)
CY (1) CY1121261T1 (enExample)
DK (1) DK3109240T3 (enExample)
ES (1) ES2704922T3 (enExample)
HR (1) HRP20182134T1 (enExample)
IL (1) IL247319B (enExample)
LT (1) LT3109240T (enExample)
MX (1) MX369217B (enExample)
MY (1) MY183605A (enExample)
PE (2) PE20161236A1 (enExample)
PH (1) PH12016501651B1 (enExample)
PL (1) PL3109240T3 (enExample)
PT (1) PT3109240T (enExample)
RS (1) RS58235B1 (enExample)
RU (1) RU2692789C2 (enExample)
SA (1) SA516371701B1 (enExample)
SG (1) SG11201606902QA (enExample)
SI (1) SI3109240T1 (enExample)
SM (1) SMT201800684T1 (enExample)
TR (1) TR201821158T4 (enExample)
TW (1) TWI651310B (enExample)
WO (1) WO2015125842A1 (enExample)
ZA (1) ZA201606449B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
KR102606064B1 (ko) * 2014-12-24 2023-11-27 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 괴사 억제제
WO2016139786A1 (ja) * 2015-03-04 2016-09-09 株式会社島津製作所 蛍光誘導体化試薬及びアミン分析方法
JP2017039714A (ja) 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
US10710967B2 (en) 2015-10-29 2020-07-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
EP3490974B1 (en) * 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
KR102538803B1 (ko) 2016-08-01 2023-06-01 앱티닉스 인크. 스피로-락탐 nmda 조정제 및 그의 사용 방법
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
WO2021016256A2 (en) * 2019-07-22 2021-01-28 Angion Biomedica Corp. Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
US11400100B2 (en) * 2019-12-11 2022-08-02 Somerset Therapeutics, Llc. Effective benzalkonium chloride-free bimatoprost ophthalmic compositions
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
US20240083867A1 (en) 2021-02-02 2024-03-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
KR20250030486A (ko) 2022-07-06 2025-03-05 아스카 세이야쿠 가부시키가이샤 피리미딘 유도체

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
WO1981003020A1 (en) * 1980-04-22 1981-10-29 Commw Scient Ind Res Org Triazine synthesis
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) * 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
AR048564A1 (es) * 1996-12-05 2006-05-10 Amgen Inc Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EA004656B1 (ru) 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
ES2398854T3 (es) 2007-04-03 2013-03-22 E. I. Du Pont De Nemours And Company Fungicidas de benceno sustituido
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Ａｄｅｋａ ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法
US8716474B2 (en) 2008-06-04 2014-05-06 Adeka Corporation Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
AU2013207289B2 (en) * 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途
JP2017039714A (ja) 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
US10710967B2 (en) * 2015-10-29 2020-07-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative

Also Published As

Publication number Publication date
JP2015172039A (ja) 2015-10-01
MX369217B (es) 2019-10-31
EP3109240A4 (en) 2017-07-26
PE20161236A1 (es) 2016-11-23
CA2936408A1 (en) 2015-08-27
PT3109240T (pt) 2019-01-21
SG11201606902QA (en) 2016-09-29
WO2015125842A1 (ja) 2015-08-27
RS58235B1 (sr) 2019-03-29
HRP20182134T1 (hr) 2019-02-08
MY183605A (en) 2021-03-02
SMT201800684T1 (it) 2019-01-11
IL247319A0 (en) 2016-09-29
CL2016002091A1 (es) 2017-01-20
JP2022120173A (ja) 2022-08-17
CY1121261T1 (el) 2020-05-29
KR20160113727A (ko) 2016-09-30
RU2016137263A (ru) 2018-03-23
RU2016137263A3 (enExample) 2018-10-04
JP6461637B2 (ja) 2019-01-30
CN106232585A (zh) 2016-12-14
TR201821158T4 (tr) 2019-01-21
PE20211548A1 (es) 2021-08-16
DK3109240T3 (en) 2018-12-17
EP3109240B1 (en) 2018-10-24
EP3456713A1 (en) 2019-03-20
JP2019065036A (ja) 2019-04-25
US20230011968A1 (en) 2023-01-12
NZ721718A (en) 2021-08-27
BR112016018341B1 (pt) 2023-02-07
KR102360699B1 (ko) 2022-02-10
TW201620881A (zh) 2016-06-16
AR099498A1 (es) 2016-07-27
PL3109240T3 (pl) 2019-03-29
EP3109240A1 (en) 2016-12-28
US12398111B2 (en) 2025-08-26
JP2021054856A (ja) 2021-04-08
US20150266834A1 (en) 2015-09-24
US20200087266A1 (en) 2020-03-19
RU2692789C2 (ru) 2019-06-27
CA2936408C (en) 2022-09-13
IL247319B (en) 2019-11-28
ES2704922T3 (es) 2019-03-20
ZA201606449B (en) 2017-11-29
LT3109240T (lt) 2019-01-10
CN106232585B (zh) 2019-04-02
BR112016018341A2 (enExample) 2017-08-08
SI3109240T1 (sl) 2019-02-28
AU2015219920B2 (en) 2018-12-20
PH12016501651A1 (en) 2017-02-06
AU2015219920A1 (en) 2016-07-14
TWI651310B (zh) 2019-02-21
MX2016010875A (es) 2016-10-26
PH12016501651B1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
SA516371701B1 (ar) مركب ترايازين واستخدامه للأغراض الطبية
SG176477A1 (en) Indole compounds
TWI288748B (en) Quinazoline derivatives
Zhang et al. Cystic kidney diseases: all roads lead to the cilium
HUE035408T2 (en) Amino-substituted imidazo [1,2-a] pyridinecarboxamides and their use
US20230024896A1 (en) Compositions and methods for cell delivery
SA518391496B1 (ar) Ret مثبطات
HUT54991A (en) Process for producing quinoline derivatives and pharmaceutical compositions comprising such compounds
SA518391033B1 (ar) مركبات أمينو ترايازول به استبدال مفيدة باعتبارها مثبطات إنزيم كيتيناز بشري
SA03240431A (ar) مركبات 3-امينو بيرازول ثلاثية الحلقه تحمل بدائل عند ذرة النتروجين بصفتها مثبطات لمعالجه اضطرابات التكاثر الخلوى
SA95160290A (ar) مشتقات كينولين
TW201408298A (zh) 免疫相關及發炎疾病之治療
HUE025013T2 (hu) Szulfonamid-származékok
EA029743B1 (ru) Модуляторы ядерного транспорта и их применение
HU227885B1 (en) Hiv protease inhibitor carboxamide-derivatives with hiv protease inhibitor effect
SA515370079B1 (ar) تركيبات وطرق لتغيير إشارة مرسال ثانية
JP2007516227A (ja) ピロール化合物およびその使用
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
SA516371205B1 (ar) مشتق يوريا أو ملح مقبول دوائياً منه
SA05260357B1 (ar) مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
TWI242012B (en) (R)-1-cyclopropyl-8-difluoromethoxy-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid methanesulfonate, its monohydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
US9562046B2 (en) Means and method for treating solid tumors
TW201039817A (en) Pyrrolidine substituted flavones as radio sensitizers
SA06270315B1 (ar) تركيبات تشمل مثبط مستقبل vegf
SA07280059B1 (ar) مشتقات 4- (3- بنزويل أمينو فينيل ) 6، 7 – داى ميثوكسى -2- ميثيل أمينو كوينازولين